Glucotrack stock spikes 34%
Investors reacted fast — Glucotrack shares jumped more than 34% on Friday after the IDE progress and new patents were disclosed. ( )
Shares opened at $1.3750 and traded as high as $1.4599 after the update, compared with a prior close of $1.09. (rttnews.com) Glucotrack said it intends to submit an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration during Q2 2026, according to its March 27, 2026 company filing. (biospace.com) The company completed a five-day, in‑hospital first‑in‑human study that assessed insertion, use and removal of an intravascular lead connected to externalized electronics, and has started a follow‑up study in Australia. (biospace.com) The U.S. Patent and Trademark Office issued three patents covering Glucotrack’s CBGM platform — US 12,453,494 (issued Oct. 28, 2025), US 12,458,257 (issued Nov. 4, 2025) and US 12,458,258 (issued Nov. 4, 2025) — protecting sensor chemistry, intravascular lead design and low‑power implantable electronics. (marketscreener.com) Management says it has built a dual‑source U.S. manufacturing strategy with two qualified contract manufacturers and has identified a U.S. reimbursement pathway to support commercial rollout. (biospace.com) The recent pop follows extreme volatility last year — the stock’s 52‑week high was $15.90 on June 25, 2025, leaving the shares more than 90% below that peak even after Friday’s gains. (stockscan.io)
